CADTH Patient EngagementActivities

DR. BRIAN O’ROURKE

CADTH PRESIDENT AND CEO

Best Medicines Coalition Annual Conference

Toronto, Ontario

November 17, 2014

Who and what is CADTH?

• Private, not-for-profit corporation

• Major producer of HTA for drugs, devices, diagnostics, and procedures

• Recognized globally as a leader in HTA

• 160 employees

• Funded by Health Canada, Provinces and Territories

CADTH Products and Services

• Drug formulary reviews

• Drug therapeutic class reviews

• Rapid response reviews

• Environmental and horizon scans

• HTA and optimal use reports

• HTA coordination and brokering services

• HTA methods guidance documents

• Education and training on HTA

CADTH Common Drug Review and pan-Canadian Oncology Drug Review

� National processes for:

• conducting objective, rigorous, and timely clinical and economic reviews of drugs, and

• providing formulary listing recommendations to participating publicly funded drug plans

Common Drug Review Update

• CDR backlog down to 7 submissions

o On track to eliminate backlog by March 2015

• Industry application fees implemented September 2014

• Study conducted recently to assess the impact of patient input to CDR

Pan-Canadian Oncology Drug Review: Phase II of Transfer

• pCODR and CDR will remain as independent programs

• Alignment of CDR and pCODR evaluation criteria

• Building on efficiencies and best practices from both programs

• Steering committee established with representation from drug plans and cancer agencies

Patient Engagement

Patients Help Define Value

Real shared decision-making ‘involves finding out

what matters to the patient – what is at stake for

them – and making judicious use of professional

knowledge and status and introducing research

evidence in a way that informs a dialogue about

what best to do, how and why.’

From Greenhalgh & Evidence Based Medicine Renaissance Group, BMJ, June 2014.

Patient Engagement at CADTH

• Common Drug Review

• pan-Canadian Oncology Drug Review

• Therapeutic Reviews

• Scientific Advice Program

• Patient Liaison Forum

What Does the Future Hold?

Patient HTA Navigator Role

• pCODR working with Canadian Cancer Action Network on a pilot project: Patient HTA Navigator

• Providing patient groups with support to optimize patient submissions for drugs under review by pCODR

o builds on the publication of A Guide for Patient Advocacy Groups: How to provide patient and caregiver input for a pCODR drug review.

Patient HTA Navigator Webinar

Webinar on November 21 from 1:00 p.m. to 2:00 p.m. – register

at www.ccanceraction.ca

CADTH’s Scientific Advice Program

• Program will offer advice to pharmaceutical companies on early drug development

• Companies will report on patient engagement activities related to clinical trial design

• CADTH will interview patient representatives to inform advice to companies

Patient Input to Medical Devices HTA

CADTH Strategic Plan 2015-2018

Includes a strategic objective on patient engagement:

“Embrace evolving successes in patient

engagement practices in health technology

assessment.”

CADTH 2015 Symposium: Student and Patient Group Award Programs

• New: Funding available for patient groups

• Not-for-profit, patient-related organizations, or citizen’s organizations interested in health policy

• Funding decisions based on financial need and contributions to conference

• Maximum award for both programs: $1,500.00

• Applications to symposium@cadth.ca by December 5, 2014

Some thoughts to consider

• Patient input to scientific advice

• Patient input to medical devices HTA

• On-going engagement to CADTH initiatives and programs (CDR and pCODR)

• A new funding model for patient groups

• Impact of patient input to HTA and funding decisions

• What are some of the evolving successes in patient engagement that CADTH should embrace?